EBMT Activity Survey Office, Division of Hematology, Department of Medicine, University Hospital, Basel, Switzerland.
Institut Paoli Calmettes Comprehensive Cancer Center & Inserm CBT-1409, Centre d'Investigations Cliniques en Biothérapies, Marseille, France.
Bone Marrow Transplant. 2021 Jul;56(7):1651-1664. doi: 10.1038/s41409-021-01227-8. Epub 2021 Feb 23.
Numbers of Hematopoietic cell transplantation (HCT) in Europe and collaborating countries continues to rise with 48,512 HCT in 43,581 patients, comprising of 19,798 (41%) allogeneic and 28,714 (59%) autologous, reported by 700 centers in 51 countries during 2019. Main indications were myeloid malignancies 10,764 (25%), lymphoid malignancies 27,895 (64%), and nonmalignant disorders 3173 (7%). A marked growth in CAR-T cellular therapies from 151 in 2017 to 1134 patients in 2019 is observed. This year's analyses focus on changes over 30 years. Since the first survey in 1990 where 143 centers reported 4234 HCT, the number has increased to 700 centers and 48,512 HCT. Transplants were reported in 20 countries in 1990, and 51, 30 years later. More than 800,000 HCT in 715,000 patients were reported overall. Next to the massive expansion of HCT technology, most notable developments include the success of unrelated donor and haploidentical HCT, an increase followed by decrease in the number of cord blood transplants, use of reduced intensity HCT in older patients, and the phenomenal rise in cellular therapy. This annual report of the European Society for Blood and Marrow Transplantation (EBMT) reflects current activity and highlights important trends vital for health care planning.
欧洲和合作国家的造血细胞移植（HCT）数量继续增加，2019 年，700 个中心在 51 个国家报告了 43581 名患者中的 48512 例 HCT，包括 19798 例（41%）异体和 28714 例（59%）自体。主要适应证为髓系恶性肿瘤 10764 例（25%）、淋巴恶性肿瘤 27895 例（64%）和非恶性疾病 3173 例（7%）。观察到嵌合抗原受体 T 细胞（CAR-T）细胞疗法从 2017 年的 151 例显著增长到 2019 年的 1134 例患者。今年的分析重点是 30 年来的变化。自 1990 年首次调查以来，143 个中心报告了 4234 例 HCT，数量增加到 700 个中心和 48512 例 HCT。1990 年报告了 20 个国家的移植，30 年后报告了 51 个国家。总体而言，报告了超过 71.5 万例患者的 80 多万例 HCT。除了 HCT 技术的大规模扩展外，最显著的发展包括非亲缘供体和半相合 HCT 的成功、紧随其后的是脐带血移植数量的减少、在老年患者中使用低强度 HCT 以及细胞治疗的惊人增长。欧洲血液和骨髓移植学会（EBMT）的这份年度报告反映了当前的活动，并强调了对医疗保健规划至关重要的重要趋势。
